Related references
Note: Only part of the references are listed.Re-epithelialization and immune cell behaviour in an ex vivo human skin model
Ana Rakita et al.
SCIENTIFIC REPORTS (2020)
Serum PD-1/PD-L1 Levels, Tumor Expression and PD-L1 Somatic Mutations in HER2-Positive and Triple Negative Normal-Like Feline Mammary Carcinoma Subtypes
Catarina Nascimento et al.
CANCERS (2020)
Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
Negar Hosseinkhani et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Relation between Immune cell response and stemness genes expression in breast cancer; A new approach in NANOG gene and Let7-a expression in breast cancer cell lines
Zeynab Aliyari-Serej et al.
IMMUNOPATHOLOGIA PERSA (2020)
Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors
Juwhan Choi et al.
IMMUNE NETWORK (2020)
Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes
Yanheng Wu et al.
NANOMEDICINE (2019)
Triple-Negative Breast Cancer: The Progress of Targeted Therapies and Future Tendencies
Christos Damaskos et al.
ANTICANCER RESEARCH (2019)
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy
Jiajing Cai et al.
ONCOTARGETS AND THERAPY (2019)
Double-slit photoelectron interference in strong-field ionization of the neon dimer
Maksim Kunitski et al.
NATURE COMMUNICATIONS (2019)
Development of double strand RNA mPEI nanoparticles and application in treating invasive breast cancer
Rui Liu et al.
RSC ADVANCES (2019)
Immunotherapy-related adverse events (irAEs): extraction from FDA drug labels and comparative analysis
QuanQiu Wang et al.
JAMIA OPEN (2019)
Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics
Rehmat Jan et al.
ADVANCED PHARMACEUTICAL BULLETIN (2019)
Anti-cancer therapy with TNFα and IFNγ:A comprehensive review
Jing Shen et al.
CELL PROLIFERATION (2018)
Treating cancer with microRNA replacement therapy: A literature review
Nayer Hosseinahli et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy
Lorenzo Mortara et al.
FRONTIERS IN IMMUNOLOGY (2018)
MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer
Takahiro Maeda et al.
CANCER RESEARCH (2018)
Breast Cancer Immunotherapy: Facts and Hopes
Leisha A. Emens
CLINICAL CANCER RESEARCH (2018)
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
Frederick Arce Vargas et al.
IMMUNITY (2017)
Caspase-8: regulating life and death
Bart Tummers et al.
IMMUNOLOGICAL REVIEWS (2017)
PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation
Sheema Almozyan et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
MYC expression correlates with PD-L1 expression in non-small cell lung cancer
Eun Young Kim et al.
LUNG CANCER (2017)
PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?
Bruna Cerbelli et al.
BIOMED RESEARCH INTERNATIONAL (2017)
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Zijun Y. Xu-Monette et al.
FRONTIERS IN IMMUNOLOGY (2017)
HMGI-C suppressing induces P53/caspase9 axis to regulate apoptosis in breast adenocarcinoma cells
Behzad Mansoori et al.
CELL CYCLE (2016)
Roles of regulatory T cells in cancer immunity
Yoshiko Takeuchi et al.
INTERNATIONAL IMMUNOLOGY (2016)
Silencing of High Mobility Group Isoform I-C ( HMGI-C) Enhances Paclitaxel Chemosensitivity in Breast Adenocarcinoma Cells (MDA-MB-468)
Behzad Mansoori et al.
ADVANCED PHARMACEUTICAL BULLETIN (2016)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ovarian Cancer Immunotherapy Using PD-L1 siRNA Targeted Delivery from Folic Acid-Functionalized Polyethylenimine: Strategies to Enhance T Cell Killing
Pei Yun Teo et al.
ADVANCED HEALTHCARE MATERIALS (2015)
The fate of chemoresistance in triple negative breast cancer (TNBC)
Elma A. O'Reilly et al.
BBA CLINICAL (2015)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Immune checkpoint receptors in regulating immune reactivity in rheumatic disease
Sabrina Ceeraz et al.
ARTHRITIS RESEARCH & THERAPY (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis
Hong Nie et al.
NATURE MEDICINE (2013)
CD44+/CD24-/low cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome
Michael O. Idowu et al.
HUMAN PATHOLOGY (2012)
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Christina Curtis et al.
NATURE (2012)
Downregulation of autophagy by Bcl-2 promotes MCF7 breast cancer cell growth independent of its inhibition of apoptosis
S. Oh et al.
CELL DEATH AND DIFFERENTIATION (2011)
Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis
Dana Briesemeister et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Characteristics of triple-negative breast cancer
Tim C. de Ruijter et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells
Shoba Amarnath et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Mark E. Davis et al.
NATURE (2010)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Inhibitory B7-family molecules in the tumour microenvironment
Weiping Zou et al.
NATURE REVIEWS IMMUNOLOGY (2008)
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors
Hazem Ghebeh et al.
NEOPLASIA (2006)
Unlocking the potential of the human genome with RNA interference
GJ Hannon et al.
NATURE (2004)
Overexpression of the notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells
ES Yvon et al.
BLOOD (2003)
Approaches for the sequence-specific knockdown of mRNA
LJ Scherer et al.
NATURE BIOTECHNOLOGY (2003)
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix
B Carnemolla et al.
BLOOD (2002)
Share Paper
